NCT06381947View on ClinicalTrials.gov

Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
DyslipidemiasStatin Adverse ReactionCardiovascular DiseasesLipid Metabolism Disorders
Interventions
DRUG

Lipid-lowering therapy combination with PCSK9 inhibitors, bempedoic acid and ezetimibe

Evaluation of therapy of bempedoic acid with PCSK9 inhibitors and ezetimibe in reducing LDL-C in statin-intolerant patients.

DRUG

Lipid-lowering therapy combination with PCSK9 inhibitors and ezetimibe

Evaluation of therapy of PCSK9 inhibitors with ezetimibe in reducing LDL-C in statin-intolerant patients.

All Listed Sponsors
lead

University of Salerno

OTHER